Trial Profile

A Randomized, Double-blind, Placebo-controlled Study of TEV-50717 (Deutetrabenazine) for the Treatment of Tourette Syndrome in Children and Adolescents

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 10 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Deutetrabenazine (Primary)
Indications Gilles de la Tourette's syndrome
Focus Therapeutic Use
Acronyms ARTISTS 1
Sponsors Teva Branded Pharmaceutical Products R&D

Most Recent Events

19 Feb 2020 Primary endpoint has not been met. (Change in the Total Tic Score (TTS) of the Yale Global Tic Severity Scale (YGTSS)), according to a Teva Pharmaceutical Industries media release.
19 Feb 2020 Results published in the Teva Pharmaceutical Industries Media Release
10 Jan 2020 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com